Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
UCART-19 / Shenzhen Feipeng Biological Therap
ChiCTR1900023500: Targeting CD19 universal chimeric antigen receptor T cells (UCART-19) in refractory/relapsed B-cell acute lymphoblastic leukemia and aggressive lymphoma	Recruiting	N/A	12		infusion of UCART-19 cells	Guangdong Second Provincial General Hospital; Guangdong Second Provincial General Hospital, Shenzhen Feipeng Biological Therapy Co. , Ltd	CD19 positive refractory/relapsed acute lymphoblastic leukemia or aggressive lymphoma